Shenzhen Weiguang Biological Products Co., Ltd. (SHE:002880)
30.85
-0.01 (-0.03%)
Feb 13, 2026, 3:04 PM CST
SHE:002880 Revenue
Shenzhen Weiguang Biological Products had revenue of 272.80M CNY in the quarter ending September 30, 2025, a decrease of -17.63%. This brings the company's revenue in the last twelve months to 1.14B, down -2.33% year-over-year. In the year 2024, Shenzhen Weiguang Biological Products had annual revenue of 1.20B with 14.75% growth.
Revenue (ttm)
1.14B
Revenue Growth
-2.33%
P/S Ratio
6.14
Revenue / Employee
1.33M
Employees
859
Market Cap
7.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.20B | 154.69M | 14.75% |
| Dec 31, 2023 | 1.05B | 380.57M | 56.98% |
| Jan 1, 2023 | 667.93M | -239.50M | -26.39% |
| Jan 1, 2022 | 907.43M | 2.87M | 0.32% |
| Dec 31, 2020 | 904.56M | 83.10M | 10.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 2.81B |
| Novogene | 2.17B |
| Xiangxue Pharmaceutical | 1.47B |
| Wuhan Keqian Biology Co.,Ltd | 1.01B |
| Beijing Konruns Pharmaceutical | 871.31M |
| GemPharmatech | 793.25M |
| R&G PharmaStudies | 789.45M |
| Zhejiang Ausun Pharmaceutical | 751.12M |